Histopathological Changes and Clinical Responses of Buruli Ulcer Plaque Lesions during Chemotherapy: A Role for Surgical Removal of Necrotic Tissue? by Ruf, Marie-Thérèse et al.
Histopathological Changes and Clinical Responses of
Buruli Ulcer Plaque Lesions during Chemotherapy: A
Role for Surgical Removal of Necrotic Tissue?
Marie-The ´re `se Ruf
1,2., Ghislain Emmanuel Sopoh
3., Luc Vale `re Brun
4, Ange Dodji Dossou
3, Yves Thierry
Barogui
5, Roch Christian Johnson
6, Gerd Pluschke
1,2*
1Swiss Tropical and Public Health Institute, Basel, Switzerland, 2University of Basel, Basel, Switzerland, 3Centre de Depistage et de Traitement de l’Ulcere de Buruli
d’Allada, Allada, Benin, 4Laboratoire d’Anatomie et Cytologie Pathologiques, Universite ´ de Parakou, Parakou, Benin, 5Centre de Depistage et de Traitement de l’Ulcere de
Buruli de Lalo, Lalo, Benin, 6Fondation Raoul Follereau, Cotonou, Be ´nin
Abstract
Background: Buruli ulcer (BU) caused by Mycobacterium ulcerans is a necrotizing skin disease usually starting with a
subcutaneous nodule or plaque, which may ulcerate and progress, if untreated, over months and years. During the currently
recommended antibiotic treatment with rifampicin/streptomycin plaque lesions tend to ulcerate, often associated with
retarded wound healing and prolonged hospital stays.
Methodology/Principal Findings: Included in this study were twelve laboratory reconfirmed, HIV negative BU patients
presenting with plaque lesions at the CDTUB in Allada, Benin. Punch biopsies for histopathological and immunohisto-
chemical analysis were taken before start of treatment and after four to five weeks of treatment. Where excision or wound
debridement was clinically indicated, the removed tissue was also analyzed. Based on clinical judgment, nine of the twelve
patients enrolled in this study received limited surgical excision seven to 39 days after completion of chemotherapy,
followed by skin grafting. Lesions of three patients healed without further intervention. Before treatment, plaque lesions
were characterized by a destroyed subcutis with extensive necrosis without major signs of infiltration. After completion of
antibiotic treatment partial infiltration of the affected tissue was observed, but large necrotic areas remained unchanged.
Conclusion/Significance: Our histopathological analyses show that ulceration of plaque lesions during antibiotic treatment
do not represent a failure to respond to antimycobacterial treatment. Based on our results we suggest formal testing in a
controlled clinical trial setting whether limited surgical excision of necrotic tissue favours wound healing and can reduce the
duration of hospital stays.
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Introduction
Buruli ulcer (BU), the third most common human mycobacte-
rial disease, is caused by M. ulcerans [1,2]. While the disease is
present in around 30 countries worldwide the main focus with the
highest prevalence is found in West African countries like Benin,
Ghana, Cameroon and the Ivory Coast [3,4]. Three categories of
pre-ulcerative lesions, painless movable subcutaneous nodules or
papules, oedema and plaques are distinguished. All three forms
of pre-ulcerative lesions may progress to ulcerative lesions, when
destruction of the subcutis is leading to the collapse of the
overlying epidermis and dermis [1,5,6].
In 2004 WHO treatment recommendations for BU changed
from a purely surgical treatment to a dual antibiotic therapy with
rifampicin and streptomycin for eight weeks [7]. Recurrence rates
after antibiotic treatment are low, but a proportion of antibiotic
treated patients, in particular those with extensively ulcerated
wounds, requires excisions and skin grafting [8–13]. During and
after completion of antibiotic treatment paradoxical reactions
associated with the enhancement of local immune responses and
increases in size of lesions may be mistaken as disease progression
[14,15]. Observational studies have shown that while nodules
usually heal after antibiotic treatment without further intervention,
ulceration and an increase in the size of the lesion is often observed
in the case of plaque lesions. These paradoxical reactions may
occur after initial improvement and often require extensive
medical care, causing long hospital stays. To elucidate the
underlying mechanisms and to gain a better insight into the
histopathological features of plaque lesions we conducted detailed
histopathological and immunohistochemical analyses of tissue
specimen from 12 plaque patients treated with rifampicin and
streptomycin.
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Ethics statement
Ethical approval (clearance Nu 011, 12/10/2010) for analyzing
patient specimens was obtained from the provisional national
ethical review board of the Ministry of Health Benin, registered
under the Nu IRB00006860. Written informed consent from the
patients or from the guardians of the patients was obtained before
surgical specimens were used for reconfirmation of clinical
diagnosis and detailed immunohistological analysis.
Study participants
12 patients aged between five and 70 years (median age 12
years) reporting between April 16 and August 15 2009 with
laboratory reconfirmed BU plaque lesions at the Centre de
Depistage et de Traitement de l’Ulcere de Buruli d’Allada in
Benin were included in the study (Table 1). Most (9/12) lesions
were located at the upper (4/12) or lower (5/12) extremities. The
diameter of the lesions was between four and 15 cm. All patients
were coming from the highly BU endemic Ze commune in the
Department Atlantique of Benin. The gender distribution was nine
males and three females. Clinical diagnosis was reconfirmed by
positive results in at least two of the three laboratory tests (IS2404
PCR, detection of acid fast bacilli (AFBs) on microscopy and
histopathology) performed. All patients completed the WHO
recommended combination dual chemotherapy with oral rifam-
picin (10 mg/kg/day) and i. m. streptomycin (15 mg/kg/day) for
56 days. All patients were tested negative for HIV.
Histopathological analysis
Punch biopsies were taken for histopathological analyses prior
to start of chemotherapy on day 22 to day 0 (T1). Of these 12 T1
samples, one was not suitable for immunohistochemical analysis. A
second punch biopsy taken 26 to 48 days after start of
chemotherapy (T2) became available from 11/12 patients.
According to the judgment of the responsible clinician, based on
the evolution of the lesions including remaining induration and
increasing lesion surface area, nine patients received adjunct
surgical treatment seven to 39 days after completion of
chemotherapy and had skin grafting five to 14 days after excision.
Samples from seven of the nine excised lesions became available
for histopathological analysis. In the case of the two other patients
that received surgery, a third punch biopsy was taken and
analyzed prior to surgical excision. Tissue samples were fixed in
4% neutral-buffered paraformaldehyde for 24 h and subsequently
transferred to 70% ethanol for transport. Biopsies were dehydrat-
ed, embedded in paraffin, cut into 5 mm thin sections and
retrieved on glass slides. After dewaxing and rehydration, sections
were stained with haematoxylin/eosin (HE) and Ziehl-Neelsen
(ZN) staining of AFBs was performed. Immunohistochemistry was
performed with antibodies against Elastase (polymorphonuclear
neutrophils [PMNs]; Dako clone NP57), CD3 (T lymphocytes;
Dako clone F7.2.38), CD8 (cytotoxic T lymphocytes; Serotec clone
4B11), CD4 (helper T lymphocytes; Dako clone 4B12), CD68
(macrophages/monocytes; Dako clone KP1), Ki67 (proliferation
marker; Dako polyclonal rabbit serum) and CD20 (B lymphocytes;
Novocastra clone7D1). Staining was performed using Vector
NovaRED and haematoxylin as a counterstain.
Author Summary
The tropical necrotizing skin disease Buruli ulcer (BU)
caused by Mycobacterium ulcerans is associated with
extensive tissue destruction and local immunosuppression
caused by the macrolide exotoxin mycolactone. Chemo-
therapy with a combination of rifampicin and streptomy-
cin for 8 weeks is the currently recommended treatment
for all types of BU lesions, including both ulcerative and
non-ulcerative stages (plaques, nodules and edema). Our
histopathological analysis of twelve BU plaque lesions
revealed extensive destruction of sub-cutaneous tissue.
This frequently led to ulceration during antibiotic treat-
ment. This should not be mistaken as a failure of the
antimycobacterial chemotherapy, since we found no
evidence for the persistence of active infection foci. Large
necrotic areas were found to persist even after completion
of antibiotic treatment. These may disturb wound healing
and the role of wound debridement should therefore be
formally tested in a clinical trial setting.
Table 1. Characteristics of the 12 Buruli ulcer plaque patients.
Patient
Ulceration
during
chemotherapy*
Time span between
end of
chemotherapy and
excision
Time span
between
excision and
skin grafting
Time span
between skin
grafting and
discharge
Time span
between start
of treatment
and discharge Sex
Age
(years)
Site of
lesion
Lesion size
at admission
1 n o n o n on o6 1 M 5 t h o r a x 6 c m 64c m
2 no no no no 55 M 12 trunk 10 cm67c m
3 yes no no no 55 M 5 face 7 cm67c m
4 no 10 14 16 95 F 13 upper leg 9 cm68c m
5 no 10 7 18 90 M 20 foot 5 cm 64c m
6 no 10 7 23 95 M 15 elbow 5 cm65c m
7 yes 10 7 36 108 F 70 knee 8 cm65c m
8 yes 7 7 33 108 M 32 upper leg 15 cm614 cm
9 yes 17 7 100 179 M 5 lower arm 12 cm610 cm
10 yes 39 5 31 130 M 12 hand 12 cm613 cm
11 yes 31 7 36 129 M 12 lower leg 10 cm68c m
12 yes 39 7 28 129 F 9 elbow 7 cm65c m
*the mean duration from start of treatment to ulceration was 30 days (11–53 days) for those five patients for which beginning of ulceration could be exactly recorded.
doi:10.1371/journal.pntd.0001334.t001
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Clinical response to antibiotic treatment
Included in this study were twelve BU patients (Tab. 1) with
single new laboratory-reconfirmed plaque lesions reporting
between April 16 and August 15, 2009 at the Centre de Depistage
et de Traitement de l’Ulcere de Buruli d’Allada in Benin. All
patients received the WHO recommended dual chemotherapy
with rifampicin and streptomycin for 56 days [7]. Seven out of 12
lesions ulcerated during chemotherapy (Fig. 1C, E, F). Six of these
patients received surgical treatment to remove necrotic tissue
(Fig. 1E, F). Based on clinical judgment, tissue was also excised
from the lesions of another three patients, which had at this stage
not yet developed ulceration, but an induration (Fig 1D). Three
patients healed without surgical intervention (Fig. 1A–C), one of
them had developed a small ulceration during chemotherapy
(Fig. 1C) which needed no further intervention.
For patients who received surgical treatment, excisions were
performed 7 to 39 days (average 19 days) after completion of
chemotherapy. Skin grafting followed 5 to 14 days (average 8 days)
after excision and patients were discharged from hospital 16 to 100
days (average 36 days) after skin grafting. The time interval
between start of antibiotic treatment till discharge from hospital
was between 55 to 179 days (average 103 days) for the 12 patients
(Tab.1). Depending on the location of the lesion this period was
prolonged by a phase of physiotherapy (Tab. 1).
Histopathological features of untreated plaque lesions
For histopathological characterization of the untreated plaque
lesions, punch biopsies were taken before start of antibiotic
treatment. Certain features, depicted in Fig. 2, were found in all
samples analyzed. The dermis presented with relatively intact
collagen with minor infiltrations around vessels and glands
(Fig. 2A, C), reflecting the pre-ulcerative nature of the plaque
lesions. Most strikingly, the subcutis was in all patients extensively
necrotic and oedematous (Fig. 2A). Additional features typical for
an untreated BU lesion, like fat cell ghosts (Fig. 2D) and minimal
infiltration limited to the surrounding of a few remaining partially
intact blood vessels (Fig. 2E), were always present. Immunohisto-
chemical staining revealed N-elastase positive neutrophilic debris
(Fig. 2F) reflecting an early wave of neutrophilic infiltration. In
addition, only few intact neutrophils (Fig. 2G) and CD68 positive
Figure 1. Presentation of BU lesions before and during therapy. Representatives of the different patient groups are depicted. A, B: Patients
with lesions that did not ulcerate and which did not require a surgical intervention. C: Patient with a lesion that ulcerated during treatment but did
not require a surgical intervention. D: Patient with a lesion that did not ulcerate but was excised; E, F: Patients with lesions that ulcerated during
treatment and needed surgical excisions. A: Patient 1; day 21, before start of treatment, punch hole visible. B: Patient 2; day 0, at the start of
treatment, punch hole visible. C: Patient 3; C1: day 22 before start of treatment; C2: day 50 after start of treatment; C3: day 300 after end of
treatment. D: Patient 5; D1: day 28 before start of treatment; D2: day 10 after end of antibiotic treatment; D3: day 17 after end of antibiotic treatment;
D4: day 35 after end of antibiotic treatment. E: Patient 10; E1: day 21 before start of treatment. E2: day 89 after start of treatment. E3: day 39 after end
of antibiotic treatment. E4: day 75 after end of antibiotic treatment. F: Patient 12; F1: day 0, at start of treatment; F2: day 26 after start of treatment;
F3: day 54 after start of treatment; F4: day 39 after end of antibiotic treatment. F5: day 72 after end of antibiotic treatment.
doi:10.1371/journal.pntd.0001334.g001
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www.plosntds.org 3 September 2011 | Volume 5 | Issue 9 | e1334Figure 2. Characteristic histopathological features of tissue samples taken before start of antibiotic treatment. Histological sections
were stained either with Haematoxylin-Eosin (HE) (A, C–E), Ziehl-Neelsen (counterstain methylenblue) (ZN) (B) or with antibodies against cell surface
or cytoplasmic markers (counterstain haematoxylin) (F–H). A: Punch biopsy with large necrotic areas, fat cell ghosts and oedema but relatively intact
epidermis and dermis. B: a band of extracellular AFBs is present in a deep layer of the necrotic subcutis. C: epidermis and dermis. D: necrotic region
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contained also a few intact CD3 positive T-cells in the dermal
tissue (data not shown).
Acid fast bacilli (AFB) were found in only 7/31 (23%) of the
tissue samples analyzed altogether. This reflects the focal
distribution of the mycobacteria and the extension of tissue
destruction, attributable to the diffusion of mycolactone, into tissue
areas with low mycobacterial burden [16]. Fig. 2B depicts an
example, where a mycobacterial focus was sampled. Here a band
of extracellular AFBs was found in a deep layer of the necrotic
subcutis.
Persistence of necrotic areas with limited infiltration in
the course of antibiotic treatment
Punch biopsies taken between 26 and 48 days after start of
antibiotic treatment typically consisted still primarily of large
oedematous necrotic areas with fat cell ghosts (Fig. 3A/B). Overall,
infiltration was much less pronounced than typically found in
ulcerative lesions at this time point of antibiotic treatment [17]. 9/
11 patients presented with a mild infiltration consisting of very few
N-elastase positive neutrophils (Fig. 3D), more CD68 positive
macrophages (Fig. 3E) and CD3 positive T-cells (Fig. 3F). These
infiltrates were scattered throughout the dermis and extended only
in 3/11 samples into the large necrotic areas. Structured infiltrates
typically found in healing BU lesions [14], were rare: granuloma
formation (Fig. 3H) was found in 2/11 samples, CD20 positive B-
cell clusters (Fig. 3G) and giant cells (Fig. 3I) in 3/11 biopsies.
AFBs were found in 4/11 samples; they were primarily
intracellular or had a ‘beaded’ appearance (Fig. 3C).
Features of tissue excised after completion of antibiotic
treatment
While lesions of three of the enrolled patients healed without
adjunct treatment, the responsible clinician decided to support
wound healing by surgical excision of affected tissue in 9/12
patients. All nine excisions were performed after completion of
antibiotic treatment, 56 to 94 days after start of chemotherapy.
While six of the nine tissue samples were excised from lesions,
which had spontaneously ulcerated during antibiotic treatment,
the other three were excised from non-ulcerated lesions showing
no adequate clinical improvement.
All nine excisions consisted to a large extent of necrotic and
oedematous tissue with fat cell ghosts (Fig. 4A). In the case of the
three patients which had still non-ulcerative lesions at the time of
excision, the dermis presented with necrosis and infiltration,
indicative for progression towards ulceration (Fig. 4C). Most (7/9)
samples showed massive infiltration of the subcutis (Fig. 4B) often
with a clear border between intact leucocytes, mainly CD14
positive macrophages/monocytes (Fig. 4D1), and the still necrotic
areas containing N-elastase positive neutrophilic debris (Fig. 4D2).
Infiltrates were mainly composed of CD68 positive macrophages
(Fig. 4E) and CD3 positive T cells (Fig. 4F) with a higher
proportion of CD8 positive (Fig. 4G) than CD4 positive (Fig. 4H)
T-cells. In addition CD68 positive langhans and foreign body
giant cells (Fig. 4I), granulomas and small CD20 positive B-cell
clusters (Fig. 4J) were found. Some areas were strongly infiltrated
with N-elastase positive neutrophils (Fig. 4K). Angiogenesis inside
the necrotic and hypoxic tissue was observed in 5/9 patients (data
not shown). Small numbers of intra- and extracellular AFB with a
beaded appearance were found in the specimens of 2/9 patients
(Fig. 4L).
Discussion
BU plaque lesions are defined as firm, painless, elevated and well
demarcated lesion with more than 2 cm in diameter [18]. Our
histopathological analysis of the tissue specimen from plaque lesions
reconfirmed earlier quantitative RT-PCR analyses [16], demon-
strating a focal distribution of the mycobacteria and a mycolactone-
mediated extension of tissue destruction to tissue areas with low
mycobacterial burden. Our studies provided no evidence for
survival of mycobacterial clusters after chemotherapy. The few
AFBs found after chemotherapy had beaded appearance and were
largely phagocytosed [17] and all tissues turned culture negative
duringtreatment.Interestingly, in those punch biopsies of untreated
BUlesions,whereamycobacterialfocuswassampled,mycobacteria
weretypicallyfoundasa band ofextracellularAFBsina deep layer-
several mm below the epidermis- of the necrotic subcutis (Fig. 2B).
This might explain why in cases, with clinical features consistent
with BU, microscopic results are frequently and PCR results are
occasionally negative. Especially when collecting diagnostic speci-
mens from non-ulcerative lesions by fine needle aspiration, also
deep layers should be sampled to increase chances to reach these
bacteria. Focal distribution of M. ulcerans and related lack of AFB
in some of the tissue samples reflects a major limitation of
histopathological analyses using punch biopsies. While findings at
a particular location of the lesion may not be representative for the
entire lesion, many major histopathological features described here
were very consistently found in all samples analyzed.
Also earlier studies [14] demonstrating a reversal of local
immune suppression during chemotherapy were confirmed. This
process starts with a diffuse chronic infiltration, primarily by
macrophages and T cells. While neutrophils play only a minor role
in this process, N-elastase positive debris in the necrotic areas are
indicative for a wave of neutrophil invasion during the early phase
of BU pathogenesis. It has been shown [14] that after an initial
phase of diffuse infiltration development of structured leukocyte
aggregates, such as B cell clusters and granulomas usually are
observed. While the development of such highly organized ectopic
lymphoid tissue was also observed in the case of plaque lesions, this
was confined to the margins of the necrotic areas. Large regions
showing massive coagulative necrosis without significant infiltra-
tion were still found in the surgical specimens excised 7–39 days
after completion of chemotherapy.
Infiltration and angiogenesis in the affected tissue during and
after chemotherapy promotes the resorption of tissue debris. Initial
inflammatory responses may be associated with paradoxical
reactions, before converging into a phase of wound healing. In
two of the 12 patients enrolled, this process of resorption of
necrotic tissue was efficient enough to permit healing without
ulceration. However, in most cases the necrotic areas of plaque
lesions seemed to be too extensive to permit complete resorption
without ulceration. In general, our histopathological analysis of
plaque lesions revealed a much larger and deeper destruction of
the subcutaneous tissue than expected. Spontaneous ulceration
during antibiotic treatment was observed in 7/12 patients and
tissue samples from three other non-ulcerated patients showed
gradual degeneration of the dermis, indicative for a progression to
ulceration. While ulceration result in the loss of necrotic tissue, our
with fat cell ghosts. E: few infiltrating cells around a blood vessel. F: N-elastase staining revealed the presence of neutrophilic debris inside the
necrotic regions. G: few intact neutrophils and H: CD68 positive infiltrating macrophages were found.
doi:10.1371/journal.pntd.0001334.g002
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sections were stained either with Haematoxylin-Eosin (HE) (A, B, H), Ziehl-Neelsen (counterstain methylenblue) (ZN) (C) or with antibodies against cell
surface or cytoplasmic markers (counterstain haematoxylin) (D–G, I). A: Punch biopsy with large necrotic areas, fat cell ghosts and oedema but
relatively intact epidermis and dermis. B: Higher magnification of necrotic tissue with large numbers of fat cell ghosts. C: Small numbers of intra and
extracellular beaded AFB. D: N-elastase positive intact neutrophils were rare. E: More intact CD68 positive macrophages and F: CD3 positive T-cells
were observed in the dermal tissue. Additionally, small CD20 positive B-cell cluster (G), few granulomas (H) and langhans giant cells (I) were found in
only few of the samples.
doi:10.1371/journal.pntd.0001334.g003
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chemotherapy from lesions that spontaneously ulcerated during
chemotherapy, revealed incomplete loss of necrotic tissue. These
findings support the decision of the responsible clinician to support
wound healing by debridement of the margins of the ulcers. It is
well documented that wound debridement i.e. the removal of
materials incompatible with healing, can substantially accelerate
the complex wound healing process [19–21]. Even if superinfec-
tions are controlled with antibiotics, chronic wounds can be caught
in a chronic inflammatory phase and debridment is then required
to convert the chronic wound bed into an acute wound and
mediate healing through the stages of inflammation, proliferation
and maturation [20]. This may also apply for BU lesions which
show massive infiltration during antibiotic treatment and may
subsequently be arrested in a chronic stage without the chance of
proper healing. In patients with severe and extensive lesions an
early decision for wound debridement may therefore reduce
hospital stays to less than 100 days.
In the present study the time span between start of treatment
and discharge from the hospital was 55–61 days for the three
Figure 4. Characteristic histopathological features of tissue surgically excised to support wound healing. Histological sections were
stained either with Haematoxylin-Eosin (HE) (A–C), Ziehl-Neelsen (counterstain methylenblue) (ZN) (L) or with antibodies against cell surface or
cytoplasmic markers (counterstain haematoxylin) (D–K). A: Overview over an excised tissue specimen still harbouring large necrotic areas with fat cell
ghosts and oedema. B: Overview over an excised tissue specimen presenting with mixed infiltration in the former necrotic region. C: Necrosis and
oedema of the dermis of an excised non-ulcerative lesion. D: CD14 (D1) and N-elastase (D2) staining revealing a clear border between infiltration with
intact CD14 positive macrophages (D1) and neutrophilic debris inside the necrotic area (D2). Infiltrated tissue areas contained large numbers of CD68
positive macrophages (E) and large numbers of CD3 positive cells (F). These belonged mainly of the CD8 (G) and not of the CD4 (H) subset. Langhans
and foreign body giant cells (I) and B-cell cluster (J) were present in the majority of the samples. Accumulations of N-elastase positive cells (K) were
occasionally found. AFB were rare, had a beaded appearance and intracellular location (L).
doi:10.1371/journal.pntd.0001334.g004
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patients, which showed no spontaneous ulceration, but were
surgically treated to remove necrotic tissue this time span was 90–
95 days. Degeneration of the dermis of the excised lesions
harbouring large areas of necrotic tissue indicated that these
patients would have developed ulceration at a later stage, leading
to a severely delayed subsequent start of the healing process. Those
six patients who showed spontaneous ulceration during chemo-
therapy and received later wound debridement, stayed for 108–
179 days in the hospital. Surgical treatment was performed 7–39
days after completion of chemotherapy and skin grafting 5–7 days
after excision. Five of these six patients were discharged from
hospital 27–38 days after skin grafting, only in one case this time
period was much longer (99d) due to secondary infection and
delayed wound healing. While bacteria are present on basically
every open wound, secondary infections above a critical bacterial
load (.10
5 organisms per gram of tissue) may lead to an arrest of
the wound healing process [22–24].
Taken together our analysis indicates that due to massive
coagulative necrosis only a minority of BU plaque lesions may heal
without spontaneous ulceration. It appears advisable to consider
debridement of ulcers that have developed in the course of
chemotherapy in order to remove necrotic tissue and to favour
wound healing. The effect of adjunct surgical treatment should
therefore be formally tested in a clinical trial setting to support
development of differentiated guidelines for BU wound manage-
ment.
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